Article Details
Retrieved on: 2024-06-21 19:50:25
Tags for this article:
Click the tags to see associated articles and topics
Summary
Vertex Pharmaceuticals' investigational stem cell-derived therapy, VX-880, significantly improved insulin production and glycemic control in Type 1 diabetes patients, reducing or eliminating the need for exogenous insulin. This biotech innovation promises transformative diabetes management.
Article found on: investors.vrtx.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here